FDG PET for detection and therapy control of metastatic germ cell tumor

Journal of Nuclear Medicine

Volumn 39, Issue 5, 1998, Pages 815-822

  Cremerius, Uwe ^a   Effert, Peter J ^a   Adam, Gerhard ^a   Sabri, Osama ^a   Zimny, Michael ^a   Wagenknecht, Gudrun ^a   Jakse, Gerhard ^a   Buell, Udalrich ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Fluorine 18 fluorodeoxyglucose; Germ cell tumor; PET; Staging; Therapy control

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER SCINTISCANNING; CANCER STAGING; CHORIOCARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EMBRYONAL CARCINOMA; FEMALE; GERM CELL TUMOR; HUMAN; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTILLATION CAMERA; SEMINOMA; TERATOCARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GERMINOMA; HUMANS; MALE; NEOPLASM, RESIDUAL; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SEMINOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031967456     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Senturia YD. The epidemiology of testicular cancer. Br J Urol 1987;60:285-291.
2. Mostofi FK, Sobin LH. International histological classification of tumours of the testis (no. 16). Geneva: WHO; 1977.
3. Garnick MB. Testicular cancer and other trophoblastic diseases. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., eds. Harrison's principles of internal medicine, 13th ed. New York: McGraw-Hill; 1994:1858-1862.
4. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 1994;44:548-552.
5. Carlsson-Farrelly E, Boquist L, Ljungberg B. Accuracy of clinical staging in non-seminomatous testicular cancer - a single center experience of retoperitoneal lymph node dissection. Scand J Urol Nephrol 1995;29:501-506.
6. Otto T, Goepel M, Seeber S, Rübben H. Delayed retroperitoneal lymph node excision in treatment of advanced nonseminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor. Urologe A 1993;32:189-193.
7. Borchers H, Sohn M, Müller-Leisse C, Fischer N, Jakse G. Growing teratoma syndrome [Abstract]. Onkologie 1991;14(suppl 4):13.
8. Rigo P, Paulus P. Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Ear J Nucl Med 1996;23:1641-1674.
9. 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995;22:508-513.
10. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637-1641.
11. Wahl RL, Greenough R, Clark MF, Grossman HB. Initial evaluation of FDG/PET imaging of metastatic testicular neoplasms. J Nucl Med 1993;34:6P.
12. 18FDG PET. J Nucl Med 1995;36:198P.
13. Reinhardt MJ, Müller-Mattheis V, Gerharz CD, Vosberg H, Ackermann R, Müller-Gärtner HW. FDG PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J Nucl Med 1997;38:99-101.
14. Cavalli F, Monfardini S, Pizzocaro G. Report on the international workshop on staging and treatment of testicular cancer. Eur J Cancer 1980;16:1367-1372.
15. Shepp LA, Vardi Y. Maximum likelihood reconstruction for positron emission tomography. IEEE Trans Med Imaging 1982;2:113-122.
16. Bares R, Klever P, Hauptmann S, et al. Fluorine-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79-86.
17. 18F-FDG PET for malignant lymphoma to evaluate cytostatic therapy. A follow-up study. In: Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology. Groningen; 1996:12-14.
18. Warren GP, Einhorn LH. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. J Clin Oncol 1995;13:2784-2788.
19. 18F-fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-548.
20. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiation therapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988;29:1521-1525.
21. Price P, Jones T. Can PET be used to detect subclinical response to cancer therapy? Eur J Cancer 1995;31A:1924-1927.
22. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients. Eur J Nucl Med 1996;23:1409-1415.
23. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intrarumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.